Immuno-PET Imaging of CD30-Positive Lymphoma Using ⁸⁹Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody

The CD30-specific antibody–drug conjugate, brentuximab vedotin, is approved for the treatment of relapsed, refractory Hodgkin lymphomas and systemic anaplastic large T-cell lymphomas. Multiple ongoing clinical trials are investigating brentuximab vedotin efficacy in other CD30-positive hematologic malignancies. Because CD30 expression varies among different types of lymphoma and can also change during the course of treatment, companion...